Amgen Inc.

Nathan Bennette

William Brett Caldwell

Dory King

Christi Hostetler

Kyle Kyburz

Kazden Ingram

Alison Viles

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

Growing community of inventors

Thousand Oaks, CA, United States of America

Nathan Bennette